Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test

Contact Dermatitis. 2021 Sep;85(3):366-368. doi: 10.1111/cod.13857. Epub 2021 Apr 23.

Authors

Luca Stingeni¹, Daniela Francisci², Leonardo Bianchi¹, Katharina Hansel¹, Marta Tramontana¹, Francesco Di Candilo², Massimo Raffaele Mannarino³, Matteo Pirro³

Affiliations

¹ Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
² Infectious Diseases Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
³ Internal Medicine Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

No abstract available

Keywords: AGEP/TEN overlap; COVID-19; SARS-CoV-2 infection; ceftriaxone; patch test; severe cutaneous adverse reaction.

Publication types

Case Reports

MeSH terms

Acute Generalized Exanthematous Pustulosis / diagnosis*
Acute Generalized Exanthematous Pustulosis / drug therapy
Acute Generalized Exanthematous Pustulosis / etiology*
Aged
Anti-Bacterial Agents / adverse effects*
Antiviral Agents / therapeutic use
COVID-19 / diagnosis
COVID-19 Drug Treatment*
Ceftriaxone / adverse effects*
Drug Therapy, Combination
Female
Humans
Patch Tests*
SARS-CoV-2

Substances

Anti-Bacterial Agents
Antiviral Agents
Ceftriaxone